SCHEMBL6949097

SCHEMBL6949097

O=C1CCC2CCC1N2Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.49
HRH3 Q9Y5N1 1/20 0.46
CHRM2 P08172 2/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ALKBH5 Q6P6C2 1/20 0.43
CHRM3 P20309 1/20 0.42
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA7 P36544 1/20 0.41
CHRNA4 P43681 1/20 0.41
MT-CO2 P00403 2/20 0.39
ALOX5 P09917 2/20 0.39
F2 P00734 1/20 0.39
PLG P00747 1/20 0.39
ELANE P08246 1/20 0.39
CTSG P08311 1/20 0.39
CMA1 P23946 1/20 0.39
CTRC Q99895 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31045767 0.91 SIGMAR1 (0.44) SIGMAR1HRH3CHRM2CHRM4CHRM5
SCHEMBL21308106 0.91 SIGMAR1 (0.44) SIGMAR1HRH3CHRM2CHRM4CHRM5
SCHEMBL17595348 0.91 SIGMAR1 (0.47) SIGMAR1HRH3CHRM2CHRM4CHRM5
Ethylene SCHEMBL6948006 0.84 SIGMAR1 (0.43) SIGMAR1ALDH1A1CHRNB2CHRNA7CHRNA4
SCHEMBL20483452 0.78 CHRM2 (0.64) SIGMAR1HRH3CHRM2CHRM4CHRM5
SCHEMBL1631416 0.77 KMT2A (0.46) SIGMAR1CHRM2CHRM4CHRM5ALKBH5
SCHEMBL928600 0.75 SIGMAR1 (0.47) SIGMAR1HRH3CHRM2CHRM4CHRM5
SCHEMBL6774733 0.75 SIGMAR1 (0.47) SIGMAR1HRH3CHRM2CHRM4CHRM5
SCHEMBL15817558 0.73 ALDH1A1 (0.44) SIGMAR1CHRM2CHRM4CHRM5ALDH1A1
SCHEMBL1723411 0.73 CHRM2 (0.58) SIGMAR1HRH3CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815909-B2 Diaminocyclohexane compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2013-07-18 US disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
WO-2013012827-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-24 WO disclosed
EP-1244450-A4 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-19 EP disclosed
EP-1244450-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP disclosed
US-6432976-B1 ANALGESICS; SIDE EFFECT REDUCTION MERCK & CO., INC. 2002-08-13 US disclosed
WO-2001032179-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed
EP-0076089-A2 Azabicycloalkane derivatives, process for their preparation, and a pharmaceutical composition containing them BEECHAM GROUP PLC (GB) 1983-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184284-A1 DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF NPY4R, NPY2R, NPY1R SIGMAR1 309/4885HRH3 142/4885CHRM2 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.